Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer
Lan Lei, Madison Canning, Elizabeth Sakach, Almeera Lateef, Larisa Kamga, Minaam Abid, Kevin Kalinsky, Shipra Gandhi · 2026
Read Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer by Lan Lei, Madison Canning, Elizabeth Sakach, Almeera Lateef, Larisa Kamga, Minaam Abid, Kevin Kalinsky, Shipra Gandhi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13529841.txt.
Description
Lan Lei and seven colleagues review new attacks on a growth pathway in the commonest breast cancer type in a 2026 paper. The cancer feeds on hormones and lacks HER2. Drugs blocking cell cycle gears work at first, then resistance grows. The PI3K to AKT to mTOR pathway often drives that escape. About forty-five percent of tumors carry a PIK3CA fault.
Narrow PI3K blockers help patients with that fault. One newer drug pairs benefit with gentler side effects. Broad blockers stumbled on toxicity. AKT blockers earned a place, with one approved in the United States. The mTOR blocker everolimus helps regardless of fault status. A dual blocker shows promise even without the fault. Next-wave drugs aim only at mutant forms. Choosing order and partners stays the open puzzle, the authors say.
Catalog record
| CREATOR | Lan Lei, Madison Canning, Elizabeth Sakach, Almeera Lateef, Larisa Kamga, Minaam Abid, Kevin Kalinsky, Shipra Gandhi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |